Videos

Kareem Karara discusses several factors impacting the affordability of biologics for patient care pathways.

JAK inhibitors’ effectiveness as a frontline treatment option for vitiligo is discussed by a key opinion leader in vitiligo treatment.

Russell, senior vice president of government markets at Priority Health, a health plan in Grand Rapids, Michigan, is one of 10 winners in this year's Emerging Industry Leaders series.

Mechanic, director of telehealth and medical director at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, is one of 10 winners in this year's Emerging Industry Leaders series.

McInerney, corporate director of population health and wellness coordination at AmeriHealth Caritas, headquartered in Philadelphia, is one of 10 winners in this year's Emerging Industry Leaders series.

Khatua, chief physician executive at Northshore Edward-Elmhurst Health, a health system based in Evanston, Illinois, is one of 10 winners in this year's Emerging Industry Leaders series.

Hu, president of Connected Networks at WellSky, a care coordination network headquartered in Boston, is one of 10 winners in this year's Emerging Industry Leaders series.

Herrera, chief executive officer and co-founder of Yuvo Health, a technology-enabled administrative and managed-care solution for federally qualified health centers based in New York City, is one of 10 winners in this year's Emerging Industry Leaders series.

Gayles, chief health officer of Hazel Health, a pediatric physical and mental telehealth provider for K-12 schools, headquartered in San Francisco, is one of 10 winners in this year's Emerging Industry Leaders series.

Study-based findings provide support for considerable implications of multiple switching between biosimilar and originator products.

Dr Rosmarin explores several treatment approaches for vitiligo, including specific options for oral repigmentation treatments.

LaFeir Fry, vice president of innovation operations at the Geisinger Health System in Danville, Pennsylvania, a regional healthcare provider and health plan, is one of 10 winners in this year's Emerging Industry Leaders series.

Davidson, vice president, employee health medical operations, at Memorial Hermann Health System, in Houston is one of 10 winners in this year's Emerging Industry Leaders series.

Dr Karara provides insight into how unbranded biologics are impacting the overall treatment landscape.

Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.

Dr Rosmarin gives a brief overview of treatment pathways.

Payers need to reframe how they view obesity as not just a health and wellness issue, but as a progressive chronic disease that needs medication, explained David Skomo, RPh, chief operations officer at WellDyne.

Nicole Bulochnik, Vice President of Drug Pricing and Network Strategy at Abarca Health delivers her presentation, "PBM-Payer Partnerships: Insight into Alternative Cost Management Strategies Across Common PBM Levels," during this year's PBMI National Annual Conference in Orlando, FL.

Thus far, value-based contracts for prescription drugs has not been transformative because of the scalability challenge for payers, explained Gregory Warren, FSA, FCA, MAAA, partner and consulting actuary with Axene Health Partners.

Cate Lockhart, MS, PharmD, PhD, Executive Director at the Biologics and Biosimilars Collective Intelligence Consortium covers her presentation "New mAbs on the Block: A Rocking Research Update on Biosimilar Uptake and Benefit Design" which she delivered at this year's PBMI national conference.

Michael Agostino, RPh, a registered pharmacist and entrepreneur of Onesto One Advisors, LLC, addressed how his career has been spent over the last few decades during his presentation Sept. 12 at this year's PBMI Annual National Conference in Orlando.

Our panel concludes with their final thoughts on using DTx and PDT management.

Three doctors discuss whether PDTs should be covered as a pharmacy benefit or medical benefit

Drs Podesta and Aungst elaborate on DTx and PDT access and the impact these therapeutics can have in the behavioral health treatment landscape.

David Rosmarin, MD, illustrates the impacts of vitiligo on patient quality of life.

Dr Karara discusses evolution of the biologics space and highlights important regulatory definitions.

Kareem Karara, PharmD, BCPS, CCHP continues this discussion on unbranded biologics, discussing payer priorities for treatment options.

Steven Pipe, MD, describes his hopes for Hemophilia B treatment in the future.

A panel of specialists focus on how real-world evidence affects the use and acceptance of digital therapeutics and prescription digital therapeutics, as well as FDA approvals.

Scott Whittle, MD, and Arwen Podesta, MD, confer about cost savings from digital therapeutics and prescription digital therapeutics from payer and provider perspectives.